+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 207 Pages
  • June 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5916057
Description Jump to:
The biologics contract manufacturing market is on an impressive upward trajectory, driven by the rising demand for novel biologics, biosimilars, and personalized medicines. With increasing outsourcing trends and the rapid advancement of biopharmaceutical technologies, contract development and manufacturing organizations (CDMOs) are playing a pivotal role in drug development and commercialization.

Market Insights

According to industry analysis, the global biologics contract manufacturing market is projected to grow from an estimated USD 21.9 billion in 2025 to USD 40.2 billion by 2032. This expansion represents a CAGR of 9.03% over the forecast period. The growing complexity of biologics, the need for specialized manufacturing platforms, and the push for reduced time-to-market are driving organizations to seek the support of experienced CDMOs.

Key Market Drivers

  • Robust Biologics Pipeline: The global biologics pipeline remains strong, with more than 1,500 biomolecules under clinical evaluation across various therapeutic areas. This steady growth supports continued outsourcing.
  • Limited In-House Capacity: Many large pharmaceutical companies face infrastructure and capacity constraints, prompting them to outsource development and production processes.
  • Next-Gen Therapeutics: There is an increasing shift toward next-generation biotherapeutics, including antibody-drug conjugates and bispecific antibodies, driving demand for innovative manufacturing solutions.
  • Technological Advancements: Single-use bioreactor systems and modular manufacturing units are providing increased flexibility, cost efficiency, and scalability.

Business Opportunity

As biopharmaceutical companies seek to enhance speed-to-market and cost efficiency, CDMOs offering integrated services are witnessing a surge in demand. Outsourcing to a single partner from molecule development to final drug product helps streamline timelines and ensures quality consistency. Partnerships and acquisitions are enabling CDMOs to expand capabilities and geographic reach. For example, Lonza and AGC Biologics have both made strategic acquisitions to expand their end-to-end service offerings in recent years.

The outsourcing trend is also being driven by biosimilar development, particularly in oncology and autoimmune diseases, where biologics dominate therapeutic approaches. Additionally, increasing adoption of mammalian cell platforms for protein production continues to shape the business Analysis.

Regional Analysis

  • United States: The U.S. dominates the North American market, attributed to a strong biotech ecosystem, high R&D expenditure, and a favorable regulatory environment. A growing number of CDMOs, research institutions, and startup collaborations are also fueling growth.
  • Germany: In Europe, Germany is emerging as a key market with a strong clinical research infrastructure and increasing outsourcing of biopharma research to control operational costs.
  • China: In Asia, China is making significant strides due to a large skilled workforce and government support for biopharmaceutical innovation. Partnerships between multinational pharma companies and local CDMOs are boosting regional development.

Key Players

Leading CDMOs in the biologics contract manufacturing market include:

  • Lonza Group AG
  • Samsung Biologics
  • WuXi Biologics (Cayman) Inc.
  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim (BioXcellence)
  • AbbVie CM
  • Thermo Fisher Scientific Inc. (Patheon N.V.)
  • Emergent BioSolutions Inc.
  • Catalent Inc.
  • AGC Biologics
  • Avid Bioservices
  • KBI Biopharma
  • Ajinomoto Bio-Pharma
  • Abzena plc
  • Rentschler Biotechnologie GmbH
  • Therapure Biopharma Inc.
  • ProBioGen AG
  • Novasep
These organizations are expanding their manufacturing capacities, introducing new platforms, and entering strategic collaborations to strengthen their market presence.

Market Challenges

Despite the positive outlook, challenges such as stringent regulatory requirements, high initial setup costs, and a shortage of skilled professionals in emerging economies hinder market growth. Moreover, supply chain vulnerabilities and inspection backlogs continue to impact timely production and delivery.

Segmentation

By Product

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Insulin
  • Interferons
  • Growth Factors
  • Others

By Platform

  • Mammalian
  • Microbial

By Therapeutic Area

  • Oncology
  • Autoimmune Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurology
  • Ophthalmology
  • Respiratory Disorders
  • Others

By Application

  • Commercial
  • Clinical

By Region

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Biologics Contract Manufacturing Demand Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2019-2024
3.1. Global Biologics Contract Manufacturing Demand Market Production Output, by Region, Value (US$ Bn) and Volume (KL), 2019-2024
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2019-2024
4.1. Global Average Price Analysis, by Product, US$ Per Unit, 2019-2024
4.2. Prominent Factor Affecting Protective Sunglasses Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit
5. Global Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
5.1. Global Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Monoclonal Antibodies
5.1.1.2. Recombinant Proteins
5.1.1.3. Vaccines
5.1.1.4. Insulin
5.1.1.5. Interferons
5.1.1.6. Growth Factors
5.1.1.7. Others
5.2. Global Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Mammalian
5.2.1.2. Microbial
5.3. Global Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Oncology
5.3.1.2. Autoimmune Disease
5.3.1.3. Metabolic Disease
5.3.1.4. Opthalmology
5.3.1.5. Cardiovascular Disease
5.3.1.6. Infectious Disease
5.3.1.7. Neurology
5.3.1.8. Respiratory Disorder
5.3.1.9. Others
5.4. Global Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Commercial
5.4.1.2. Clinical
5.5. Global Biologics Contract Manufacturing Demand Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2032
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
6.1. North America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Monoclonal Antibodies
6.1.1.2. Recombinant Proteins
6.1.1.3. Vaccines
6.1.1.4. Insulin
6.1.1.5. Interferons
6.1.1.6. Growth Factors
6.1.1.7. Others
6.2. North America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Mammalian
6.2.1.2. Microbial
6.3. North America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Oncology
6.3.1.2. Autoimmune Disease
6.3.1.3. Metabolic Disease
6.3.1.4. Opthalmology
6.3.1.5. Cardiovascular Disease
6.3.1.6. Infectious Disease
6.3.1.7. Neurology
6.3.1.8. Respiratory Disorder
6.3.1.9. Others
6.4. North America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Commercial
6.4.1.2. Clinical
6.5. North America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1. Key Highlights
6.5.1.1. U.S. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.2. U.S. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.3. U.S. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.4. U.S. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.5. Canada Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.6. Canada Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.7. Canada Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.1.8. Canada Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
7.1. Europe Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Monoclonal Antibodies
7.1.1.2. Recombinant Proteins
7.1.1.3. Vaccines
7.1.1.4. Insulin
7.1.1.5. Interferons
7.1.1.6. Growth Factors
7.1.1.7. Others
7.2. Europe Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Mammalian
7.2.1.2. Microbial
7.3. Europe Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Oncology
7.3.1.2. Autoimmune Disease
7.3.1.3. Metabolic Disease
7.3.1.4. Opthalmology
7.3.1.5. Cardiovascular Disease
7.3.1.6. Infectious Disease
7.3.1.7. Neurology
7.3.1.8. Respiratory Disorder
7.3.1.9. Others
7.4. Europe Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Commercial
7.4.1.2. Clinical
7.5. Europe Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Germany Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.2. Germany Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.3. Germany Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.4. Germany Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.5. U.K. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.6. U.K. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.7. U.K. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.8. U.K. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.9. France Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.10. France Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.11. France Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.12. France Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.13. Italy Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.14. Italy Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.15. Italy Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.16. Italy Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.17. Turkey Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.18. Turkey Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.19. Turkey Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.20. Turkey Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.21. Russia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.22. Russia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.23. Russia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.24. Russia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.25. Rest of Europe Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.26. Rest of Europe Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.27. Rest of Europe Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.1.28. Rest of Europe Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
8.1. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Monoclonal Antibodies
8.1.1.2. Recombinant Proteins
8.1.1.3. Vaccines
8.1.1.4. Insulin
8.1.1.5. Interferons
8.1.1.6. Growth Factors
8.1.1.7. Others
8.2. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Mammalian
8.2.1.2. Microbial
8.3. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Oncology
8.3.1.2. Autoimmune Disease
8.3.1.3. Metabolic Disease
8.3.1.4. Opthalmology
8.3.1.5. Cardiovascular Disease
8.3.1.6. Infectious Disease
8.3.1.7. Neurology
8.3.1.8. Respiratory Disorder
8.3.1.9. Others
8.4. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Commercial
8.4.1.2. Clinical
8.5. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1. Key Highlights
8.5.1.1. China Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.2. China Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.3. China Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.4. China Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.5. Japan Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.6. Japan Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.7. Japan Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.8. Japan Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.9. South Korea Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.10. South Korea Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.11. South Korea Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.12. South Korea Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.13. India Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.14. India Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.15. India Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.16. India Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.17. Southeast Asia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.18. Southeast Asia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.19. Southeast Asia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.20. Southeast Asia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
9.1. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
9.1.1. Key Highlights
9.1.1.1. Monoclonal Antibodies
9.1.1.2. Recombinant Proteins
9.1.1.3. Vaccines
9.1.1.4. Insulin
9.1.1.5. Interferons
9.1.1.6. Growth Factors
9.1.1.7. Others
9.2. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
9.2.1.1. Mammalian
9.2.1.2. Microbial
9.3. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
9.3.1. Key Highlights
9.3.1.1. Oncology
9.3.1.2. Autoimmune Disease
9.3.1.3. Metabolic Disease
9.3.1.4. Opthalmology
9.3.1.5. Cardiovascular Disease
9.3.1.6. Infectious Disease
9.3.1.7. Neurology
9.3.1.8. Respiratory Disorder
9.3.1.9. Others
9.4. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
9.4.1. Key Highlights
9.4.1.1. Commercial
9.4.1.2. Clinical
9.5. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1. Key Highlights
9.5.1.1. Brazil Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.2. Brazil Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.3. Brazil Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.4. Brazil Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.5. Mexico Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.6. Mexico Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.7. Mexico Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.8. Mexico Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.9. Argentina Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.10. Argentina Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.11. Argentina Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.12. Argentina Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.13. Rest of Latin America Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.14. Rest of Latin America Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.15. Rest of Latin America Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.1.16. Rest of Latin America Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
10.1. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.1.1. Key Highlights
10.1.1.1. Monoclonal Antibodies
10.1.1.2. Recombinant Proteins
10.1.1.3. Vaccines
10.1.1.4. Insulin
10.1.1.5. Interferons
10.1.1.6. Growth Factors
10.1.1.7. Others
10.2. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
10.2.1. Key Highlights
10.2.1.1. Mammalian
10.2.1.2. Microbial
10.3. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
10.3.1. Key Highlights
10.3.1.1. Oncology
10.3.1.2. Autoimmune Disease
10.3.1.3. Metabolic Disease
10.3.1.4. Opthalmology
10.3.1.5. Cardiovascular Disease
10.3.1.6. Infectious Disease
10.3.1.7. Neurology
10.3.1.8. Respiratory Disorder
10.3.1.9. Others
10.4. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
10.4.1. Key Highlights
10.4.1.1. Commercial
10.4.1.2. Clinical
10.5. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1. Key Highlights
10.5.1.1. GCC Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.2. GCC Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.3. GCC Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.4. GCC Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.5. South Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.6. South Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.7. South Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.8. South Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.9. Egypt Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.10. Egypt Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.11. Egypt Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.12. Egypt Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.13. Nigeria Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.14. Nigeria Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.15. Nigeria Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.16. Nigeria Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. Artery Type vs Indication Heatmap
11.2. Manufacturer vs Indication Heatmap
11.3. Company Market Share Analysis, 2025
11.4. Competitive Dashboard
11.5. Company Profiles
11.5.1. Samsung Biologics
11.5.1.1. Company Overview
11.5.1.2. Product Portfolio
11.5.1.3. Financial Overview
11.5.1.4. Business Strategies and Development
11.5.2. BioXcellence (Boehringer Ingelheim)
11.5.2.1. Company Overview
11.5.2.2. Product Portfolio
11.5.2.3. Financial Overview
11.5.2.4. Business Strategies and Development
11.5.3. Lonza Group AG
11.5.3.1. Company Overview
11.5.3.2. Product Portfolio
11.5.3.3. Financial Overview
11.5.3.4. Business Strategies and Development
11.5.4. Fujifilm Diosynth Biotechnologies
11.5.4.1. Company Overview
11.5.4.2. Product Portfolio
11.5.4.3. Financial Overview
11.5.4.4. Business Strategies and Development
11.5.5. AbbVie CM (AbbVie Inc.)
11.5.5.1. Company Overview
11.5.5.2. Product Portfolio
11.5.5.3. Financial Overview
11.5.5.4. Business Strategies and Development
11.5.6. WuXi Biologics (Cayman) Inc.
11.5.6.1. Company Overview
11.5.6.2. Product Portfolio
11.5.6.3. Financial Overview
11.5.6.4. Business Strategies and Development
11.5.7. AGC Biologics
11.5.7.1. Company Overview
11.5.7.2. Product Portfolio
11.5.7.3. Financial Overview
11.5.7.4. Business Strategies and Development
11.5.8. Patheon N.V. (Thermo Fisher Scientific Inc.)
11.5.8.1. Company Overview
11.5.8.2. Product Portfolio
11.5.8.3. Financial Overview
11.5.8.4. Business Strategies and Development
11.5.9. Emergent BioSolutions Inc.
11.5.9.1. Company Overview
11.5.9.2. Product Portfolio
11.5.9.3. Financial Overview
11.5.9.4. Business Strategies and Development
11.5.10. Ajinomoto Bio-Pharma
11.5.10.1. Company Overview
11.5.10.2. Product Portfolio
11.5.10.3. Financial Overview
11.5.10.4. Business Strategies and Development
11.5.11. Avid Bioservices, Inc.
11.5.11.1. Company Overview
11.5.11.2. Product Portfolio
11.5.11.3. Financial Overview
11.5.11.4. Business Strategies and Development
11.5.12. KBI Biopharma
11.5.12.1. Company Overview
11.5.12.2. Product Portfolio
11.5.12.3. Financial Overview
11.5.12.4. Business Strategies and Development
11.5.13. Rentschler Biotechnologie GmbH
11.5.13.1. Company Overview
11.5.13.2. Product Portfolio
11.5.13.3. Financial Overview
11.5.13.4. Business Strategies and Development
11.5.14. Merck KGaA
11.5.14.1. Company Overview
11.5.14.2. Product Portfolio
11.5.14.3. Financial Overview
11.5.14.4. Business Strategies and Development
11.5.15. Catalent Inc.
11.5.15.1. Company Overview
11.5.15.2. Product Portfolio
11.5.15.3. Financial Overview
11.5.15.4. Business Strategies and Development
11.5.16. Therapure Biopharma Inc.
11.5.16.1. Company Overview
11.5.16.2. Product Portfolio
11.5.16.3. Financial Overview
11.5.16.4. Business Strategies and Development
11.5.17. Novasep
11.5.17.1. Company Overview
11.5.17.2. Product Portfolio
11.5.17.3. Financial Overview
11.5.17.4. Business Strategies and Development
11.5.18. Abzena plc.
11.5.18.1. Company Overview
11.5.18.2. Product Portfolio
11.5.18.3. Financial Overview
11.5.18.4. Business Strategies and Development
11.5.19. ProBioGen AG
11.5.19.1. Company Overview
11.5.19.2. Product Portfolio
11.5.19.3. Financial Overview
11.5.19.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Companies Mentioned

  • Samsung Biologics
  • BioXcellence (Boehringer Ingelheim)
  • Lonza Group AG
  • Fujifilm Diosynth Biotechnologies
  • AbbVie CM (AbbVie Inc.)
  • WuXi Biologics (Cayman) Inc.
  • AGC Biologics
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Emergent BioSolutions Inc.
  • Ajinomoto Bio-Pharma
  • Avid Bioservices, Inc.
  • KBI Biopharma
  • Rentschler Biotechnologie GmbH
  • Merck KGaA
  • Catalent Inc.
  • Therapure Biopharma Inc.
  • Novasep
  • Abzena plc.
  • ProBioGen AG

Related Topics

Related Reports

Biologics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing and Geography - Product Image

Biologics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing and Geography

  • Report
  • 200 Pages
  • Global
From
Spine Biologics Market by Product, by End-user, and by Region - Product Image

Spine Biologics Market by Product, by End-user, and by Region

  • Report
  • 200 Pages
  • Global
From
Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Development Market Report 2025 - Product Image

Biologics Contract Development Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030 - Product Image

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.